Cerevel Therapeutics Holdings Inc (FRA:673)
€ 23.6 0 (0%) Market Cap: 7.57 Bil Enterprise Value: 7.13 Bil PE Ratio: 0 PB Ratio: 14.49 GF Score: 20/100

Cerevel Therapeutics Holdings Inc at JPMorgan Healthcare Conference Transcript

Jan 10, 2023 / 04:15PM GMT
Release Date Price: €23.4
Jessica Macomber Fye
JPMorgan Chase & Co, Research Division - Analyst

Great. Good morning, everyone. My name is Jess Fye. I'm a large cap biotech analyst at JPMorgan. And we're continuing the conference this morning with Cerevel. A little different format this year, so we're not going to do the whole switching rooms thing for Q&A.

After Tony's presentation, we're going to go straight into Q&A in this room. There's 2 ways to ask a question, you can raise your hands, someone will bring you a mic or you can submit your questions electronically, and send it to an iPad, and I'll read the question for you.

So with that, let me pass it over to Cerevel CEO, Tony Coles.

N. Anthony Coles
Cerevel Therapeutics Holdings, Inc. - Executive Chairman

Thank you, Jess, and good morning, everyone. It's certainly terrific to be back in San Francisco for one of the first large in-person JPMorgan. I'm happy to be here and to be with you this morning to tell you the tale -- the improbable story of the company of Cerevel that is really working to do

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot